Review of outcomes associated with formulary restrictions: Focus on step therapy

American Journal of Pharmacy Benefits

Volumn 2, Issue 1, 2010, Pages 50-58

  Carlton, Rashad I ^a   Bramley, Thomas J ^a   Nightengale, Brian ^a   Conner, Therese M ^b   Zacker, Christopher ^c  

^a XCENDA   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DRUG COST; DRUG FORMULARY; HEALTH CARE ACCESS; HEALTH CARE COST; MEDICAL LITERATURE; PATIENT SATISFACTION; TREATMENT PLANNING;

EID: 77953444771     PISSN: 19454481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Litton LM, Sisk FA, Atkins ME. Managing drug costs: the perception of managed care pharmacy directors. Am J Manag Care. 2000;6(7):805-814.
2. Malkin JD, Goldman DP, Joyce GF. The changing face of pharmacy benefit design. Health Aff (Millwood). 2004;23(1):194-199.
3. Murawski MM, Abdelgawad T. Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid. Am J Manag Care. 2005;11(spec No):SP35-SP42.
4. Miller S, Parker A, Peterson C, et al. 2005 Drug Trend Report. St. Louis, MO: Express Scripts Inc; June 2006.
5. Dunn JD, Cannon HE, Mitchel MP, Curtiss FR. Utilization and drug costs outcomes of a step-therapy edit for generic antidepressant in an HMO in an integrated health system. J Manag Care Pharm. 2006;12(4):294-302.
6. Yokoyama K, Yang W, Preblick R, Frech-Tamas F. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. J Manag Care Pharm. 2007;13(3):235-244.
7. Motheral BR, Henderson R, Cox ER. Plan-sponsor savings and member experience with point-of-service prescription step therapy. Am J Manag Care. 2004;10(7, pt 1):457-464.
8. Cox ER, Henderson R, Motheral BR. Health plan member experience with point-of-service prescription step therapy. J Manag Care Pharm. 2004;10(4):291-298.
9. Ganther-Urmie JM, Nair KV, Valuck R, McCollum M, Lewis SJ, Turpin RS. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans. Am J Manag Care. 2004;10(3):201-208.
10. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22): 2349-2359.
11. Panzer PE, Regan TS, Chiao E, Sarnes MW. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders. Am J Manag Care. 2005;11(12 suppl):S370-S379.
12. Abourjaily P, Gouveia WA, Selker HP, Zucker DR. Evaluating the nondrug costs of formulary coverage restrictions. Manag Care. 2005;14(8):50-57, 62.
13. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332-337.
14. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of a 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care. 2005;11(10):621-628.
15. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. J Am Med Assoc. 2004;291(19):2344-2350.
16. Taira DA, Wong K, Frech F, Frech-Tamas F, Chung RS. Co-payment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12(11):678-683.
17. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003;43(2):173-184.
18. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5 suppl):S170-S176.
19. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood). 2004;23(1):135-146.
20. Arthur Andersen LLP, for the National Association of Chain Drug Stores Education Foundation. Pharmacy Activity Cost and Productivity Study. November 1999. http://www.nacds.org/wmspage.cfm?parm1=609. Accessed May 1, 2007.
21. Testimony of Ellen Leitzer, Executive Director, Health Assistance Partnership, before the Senate Committee on Aging. January 31, 2007. http://aging.senate.gov/minority/-files/hr167el.pdf. Accessed April 19, 2007.
22. American Diabetes Association. Third-party reimbursement for diabetes care, self-management education, and supplies. Diabetes Care. 2005;28(suppl 1):S62-S63.
23. Gleason PP. Assessing step-therapy programs: a step in the right direction. J Manag Care Pharm. 2007;13(3):273-275.